ClinicalTrials.gg
CompletedNCT06099184VERONAUpdated Mar 4, 2025

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

A Phase 2 interventional study of EYP-1901 and Aflibercept 2Mg/0.05Ml Inj,Oph in Diabetic Macular Edema, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
152nd of 244
27 · median 45
Started
2024
with 8 others
Phase 2
63 of 276
3 open now
Registered
249th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 152nd largest by enrollment of the 244 interventional ones that give a count, is one of 9 that started in 2024, is one of 63 in phase 2, and was the 249th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept

Read the detailed description

A study to evaluate Efficacy and Safety of two doses of EYP-1901 in subjects with DME

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • EYP-1901
  • EyePoint
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit
  • Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit.
  • BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).

Exclusion criteria

Exclusion Criteria:

  • Any current or history of ocular disease other than DME
  • BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.
  • Active ocular inflammation or active infection in either eye at Baseline (Day 1).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    EYP-1901 1343 µg

    EYP-1901 1343 µg, single dose

    Drug: EYP-1901

  • Experimental
    EYP-1901 2686 µg

    EYP-1901 2686 µg, single dose

    Drug: EYP-1901

  • Active comparator
    Aflibercept

    Aflibercept 2 mg/0.05mL solution, single dose

    Drug: Aflibercept 2Mg/0.05Ml Inj,Oph

Interventions

  • Intravitreal Injection

    Also known as: Vorolanib

  • DrugAflibercept 2Mg/0.05Ml Inj,Oph

    Drug page: Aflibercept

    Intravitreal Injection

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept

    Timing of supplemental injection

    Time frame: Week 24

Secondary outcomes

  1. Change in best corrected visual acuity (BCVA)

    Changes in BCVA

    Time frame: Week 24

07

Study locations

6 sites
  • EyePoint Investigative Site
    Phoenix, Arizona 85020, United States
  • EyePoint Investigative Site
    Lemont, Illinois 60439, United States
  • EyePoint Investigative Site
    Hagerstown, Maryland 21740, United States
  • EyePoint Investigative Site
    Reno, Nevada 89502, United States
  • EyePoint Investigative Site
    Erie, Pennsylvania 16507, United States
  • EyePoint Investigative Site
    Lynchburg, Virginia 24502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2024, 9 months.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 9 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Jan 15, 2024
Primary completionActual
Oct 24, 2024
CompletionActual
Oct 24, 2024
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06099184
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jan 15, 2024
Primary completion
Oct 24, 2024
Completion
Oct 24, 2024
Last update
Mar 4, 2025

Study contacts

Ramiro Ribeiro, MD
study director · EyePoint Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion